Muscular Dystrophy & Sevasemten
Servier Acquires Our Muscular Dystrophy Program
Following the close of our transaction with Servier, Edgewise’s muscular dystrophy business, including sevasemten, is now part of Servier. Servier’s global capabilities and commitment to neuromuscular diseases position it to advance sevasemten and continue supporting the patient and advocacy communities we have been privileged to serve.
Edgewise is now focused exclusively on advancing high-impact therapies for people living with serious cardiovascular diseases.
Muscular Dystrophy
In muscular dystrophies like Becker and Duchenne, muscle contraction with everyday movements causes muscle damage in the absence of fully functioning protective proteins. Over time, muscle fibers get replaced with fat and scar tissue. This disease process is called “contraction-induced muscle damage” and it is the root cause of functional challenges linked to serious muscle diseases like Becker and Duchenne, as well as other muscular dystrophies. Protecting muscle is a key goal in the management of muscular dystrophies.
Becker Muscular Dystrophy
Becker is a genetic, progressive neuromuscular disorder that imposes significant physical, emotional, financial and social impacts predominantly on males and their caregivers. Genetic mutations in the dystrophin gene resulting in Becker lead to contraction-induced muscle damage, which is the primary driver of muscle loss and impaired motor function in muscular dystrophies. Functional decline can begin at any age, and once that muscle loss begins, the decline in function is irreversible and continuous.
Duchenne Muscular Dystrophy
Duchenne is a severe, degenerative muscle disorder with a median life expectancy of around 30 years old. People living with Duchenne begin to lose their ability to walk without assistance by their early teens and nearly all will require the use of a wheelchair by the time they are in their mid-teens. Duchenne is the most common type of muscular dystrophy, and genetic mutations in the dystrophin gene result in contraction-induced muscle damage, which is the primary driver of irreversible muscle loss and impaired motor function.
Individuals Living with Muscular Dystrophies
Sevasemten
Sevasemten is an orally administered first-in-class fast skeletal myosin inhibitor designed to preserve and protect unstable muscle against contraction-induced damage in individuals living with muscular dystrophies, including Becker and Duchenne.
Sevasemten is an investigational therapy that has not been approved for use in Becker muscular dystrophy or Duchenne muscular dystrophy by any regulatory agency, as its safety and effectiveness have not been established for the treatment of these diseases.
For inquiries related to sevasemten or the muscular dystrophy program, now part of Servier, please contact Servier directly.
